

©Borgis

Mariola Wyględowska-Kania¹, *Joanna Gola², Anna Uttecht-Pudełko², Dominika Wcisło-Dziadecka⁴, Małgorzata Kaprał³, Barbara Strzałka-Mrozik², Celina Kruszniewska-Rajs², Magdalena Tkacz⁵, Urszula Mazurek², Ligia Brzezińska-Wcisło¹

Defensin *DEFB4A* transcript level in the differentiation of keratoacanthoma, squamous and basal cell carcinomas**

Poziom ekspresji defensyny *DEFB4A* w różnicowaniu rogowia kolczystokomórkowego, raka kolczystokomórkowego i raka podstawnkomórkowego

¹School of Medicine in Katowice, Medical University of Silesia in Katowice, Department of Dermatology
Head of Department: prof. Ligia Brzezińska-Wcisło, MD, PhD

²School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, Department of Molecular Biology
Head of Department: prof. Urszula Mazurek, PhD

³School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, Department of Biochemistry
Head of Department: prof. Ludmiła Węglarz, PhD

⁴School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, Department of Skin Structural Studies
Head of Department: Associate Professor of Biology Krzysztof Jasik, PhD

⁵School of Computer Science and Material Science, University of Silesia in Katowice, Institute of Computer Science, Division of Information Systems
Head of Division: prof. Mariusz Boryczka, PhD

Key words

defensin *DEFB4A*, non-melanoma skin cancers, oligonucleotide microarrays (Affymetrix), real-time QRT-PCR

Słowa kluczowe

defensyna *DEFB4A*, niemelanotyczne nowotwory skóry, mikromacierze oligonukleotydowe (Affymetrix), QRT-PCR w czasie rzeczywistym

Address/adres:

*Joanna Gola
Department of Molecular Biology
SPLMS SUM
ul. Jedności 8, 41-100 Sosnowiec
tel. +48 (32) 364-10-27
fax +48 (32) 364-10-20
jgola@sum.edu.pl

S u m m a r y

Introduction. Defensins are peptide with antimicrobial, antiviral, antifungal activities and many other functions, such as induction of immunological response and antitumor activity. Changes in expression level of defensins was studied in many skin pathologies, including dermatological lesions such as psoriasis, atopic dermatitis and non-melanoma skin cancers (squamous cell carcinoma – SCC and basal cell carcinoma – BCC).

Aim. The objective of this study was to evaluate the mRNA profile of defensin-related genes' transcripts as an additional molecular marker of non-melanoma skin pathologies: SCC, BCC and keratoacanthoma (KA).

Material and methods. Tissue samples were obtained from the central part of tumours (KA, SCC and BCC) and healthy margins. mRNA profile of genes coding defensins and proteins involved in their activation was determined using oligonucleotide microarrays (Affymetrix). Validation of the microarray analysis was performed using real-time QRT-PCR.

Results. Microarray analysis revealed changes in defensin-related genes' profile. In all tumours *DEFB4A* (*defensin beta 2*) mRNA was up-regulated, compared with the healthy skin margins. Real-time QRT-PCR analysis showed increased *DEFB4A* transcript level both in KA and SCC comparing to BCC.

Conclusions. Defensin beta 2 mRNA level is a useful tool for the differentiation of KA and SCC from BCC. KA and SCC cannot be differentiated on the basis of the *DEFB4A* mRNA level.

S t r e s z c z e n i e

Wstęp. Defensyny stanowią grupę peptydów o aktywności antybakteryjnej, antywirusowej i antygrzybiczej. Uczestniczą także w indukcji odpowiedzi immunologicznej i przeciwnowotworowej. Zmiany w poziomie ekspresji defensyn były badane w wielu patologich skórnych, m.in. w łuszczycy, atopowym zapaleniu skóry, a także w niemelanotycznych nowotworach skóry (raku kolczystokomórkowym – SCC i raku podstawnkomórkowym – BCC).

Cel pracy. Celem tej pracy była ocena profilu mRNA genów kodujących defensyny oraz białka zaangażowane w indukcję ich ekspresji jako dodatkowego markera niemelanotycznych patologii skórnych: SCC, BCC i rogowia kolczystokomórkowego (KA).

**The work was supported by the Medical University of Silesia (KNW-1-059/P/1/0). This research was supported in part by PL-Grid Infrastructure.

Materiał i metody. Wycinki uzyskano z centralnej części guza (KA, SCC i BCC) i marginesów tkanki zdrowej. Profil mRNA genów kodujących defensyny oraz białka zaangażowane w indukcję ich ekspresji został wyznaczony techniką mikromacierzy oligonukleotydowych (Affymetrix). Walidację wyników przeprowadzono techniką QRT-PCR w czasie rzeczywistym.

Wyniki. Analiza techniką mikromacierzy wykazała zmiany profilu mRNA genów powiązanych z defensynami. We wszystkich guzach stwierdzono nadekspresję mRNA defensyny 2 (ang. *defensin beta 2 – DEFB4A*), w porównaniu do kontroli. Analiza techniką QRT-PCR w czasie rzeczywistym wykazała wzrost liczby kopii mRNA *DEFB4A* zarówno w KA, jak i SCC w porównaniu do BCC.

Wnioski. Poziom mRNA defensyny 2 jest przydatnym narzędziem w różnicowaniu KA i SCC od BCC. Rogowiak kolczystokomórkowy i rak kolczystokomórkowy nie mogą być różnicowane na podstawie liczby kopii mRNA *DEFB4A*.

INTRODUCTION

Defensins play a role as peptide antibiotics and constitute an important element of anti-infectious protection (1). Apart from a direct antimicrobial action, defensins also have many other functions, such as antifungal and antiviral activities, and chemotactic activity towards dendritic cells, T cells, basal cells and neutrophils. They may induce the production of certain chemokines and proinflammatory mediators; regulate complement activity; inhibit fibrinolysis and the production of certain glucocorticosteroids; intensify the proliferation of lymphocytes, endothelial cells and fibroblasts; bind and neutralize endotoxins; stimulate healing of sores; induce degranulation of basal cells and show antitumor activity (2). There are three groups of defensins – defensin α and β , and θ defensins – generated during the cyclisation of the two α defensins (1). In humans, six α (HNP 1-6 – human neutrophil peptide) and four β defensins (HBD 1-4) have been identified (3). Changed expression level of defensins was reported in many pathologies, including dermatological lesions such as psoriasis, acne vulgaris and atopic dermatitis (3-5). Examinations of cancer samples such as oesophageal squamous cell carcinoma, primary cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) also showed changes in defensins profile, suggesting their potential participation in these pathologies (6-8).

Knowledge of molecular markers of tumour transformation is essential for malignant diseases because it enables a diagnosis to be made of a disease already at the level of molecular changes, and it aids cause-directed and efficient therapy. Non-melanoma skin cancers are still problematic in diagnosis because of clinical features resembling other pathologies i.e. keratoacanthoma. Keratoacanthoma (KA) is a relatively low-grade malignancy that histologically and clinically resembles well-differentiated SCC (9, 10). It develops on unchanged skin in the form of a dome shaped, well-limited, hard nodule, usually with the same colour as the surrounding skin. The central part of the tumour has a crater-like depression with embanked margins, filled up with a keratin mass (11, 12). KA is characterised by sometimes fast growth and a tendency to regression with scarring (11). BCC is the most common type of epithelial cancer; it is characterised by low clinical and histological malignancy and slow growth

and rarely metastasises (13, 14). It is usually found on unchanged skin of the face and head and spreads in multiple directions with edgings. The multiple and multifocal presence of BCC is classified as nevoid BCC syndrome (Gorlin-Goltz syndrome) (13, 14). Clinically, the changes can be highly differentiated, superficial, corneous, nevus-like, scleroderma-like, nodular or sore-like (15). SCC is the second most frequent (after BCC) skin cancer. It originates from squamous epithelium and develops from premalignant states (leucoplakia). It is characterised by fast growth and metastases to regional lymph nodes. Clinical forms of SCC (sore and papular) morphologically resemble KA and BCC (9, 16). Therefore additional markers could facilitate diagnosis of non-melanoma skin pathologies.

Significant risk factors for BCC, SCC and KA are: UV radiation, ionized radiation, post-infectious and post-drug immunosuppression, chemical carcinogens (arsenic, wood tars), old age, male gender, light skin type and human papilloma virus infection (8, 9, 16-20). Most of these factors influence immunological response. Due to its multidirectional activity, defensins may be involved not only in the molecular pathogenesis of non-melanoma skin cancers, but also in the immunological reaction leading to self-regression of KA. Understanding of the molecular mechanisms underlying KA regression may contribute to the development of an efficient treatment for skin cancers. Better knowledge about defensins level in non-melanoma skin pathologies could improve their diagnosis and could affect better understanding of molecular mechanism underlying these pathologies. Till this time there is no research comparing defensins profile in these three non-melanoma pathologies (KA, SCC and BCC) in one study.

AIM

The aim of this work was to evaluate the mRNA profile of defensin family transcripts as an additional molecular marker of nonmelanoma skin pathologies.

MATERIAL AND METHODS

The study included a group of 39 patient (16 females and 23 males; mean age 71.8 ± 9.5 years) diagnosed and treated in the Dermatology Clinics and Department of Medical University of Silesia in Katowice. Based on clinical and pathomorphological

examination, 9 cases were keratoacanthoma (KA), 11 were squamous cell carcinoma (SCC) and 19 were basal cell carcinoma (BCC). The changes were located on the skin of the face and head. The biopsies for the pathomorphological and molecular examination were obtained from the centre of the tumour and the margins of healthy tissues where no tumour cells were found. After surgical removal, the samples were immediately preserved in the RNA stabilisation reagent RNAlater (Qiagen GmbH, Hilden, Germany). For microarray analysis 19 samples (6 KA, 3 SCC, 7 BCC and 4 margins of healthy tissues) were selected. The study was approved by the Bioethical Commission of the Medical University of Silesia. All of the patients were informed about the research and signed an informed consent form.

RNA extraction

Total RNA was extracted from the tissue samples using TRIZOL[®] reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. Total RNA extracts were treated with DNase I (MBI Fermentas, Vilnius, Lithuania) and purified with a RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's protocol. The quality of RNA was estimated by electrophoresis on 1% agarose gel stained with ethidium bromide. The RNA concentration was determined on the basis of absorbance values at 260 nm using a Gene Quant Pro spectrophotometer (LKB Biochrom Ltd., Cambridge, UK).

Microarray analysis

The analysis of the expression profile of defensin-related genes was performed using commercially available oligonucleotide microarrays HG-U133A (Affymetrix, Santa Clara, CA) according to the manufacturer's protocol. For finding significant genes comparative analysis was performed with the use of GeneSpring 12.6.1 platform (Agilent Technologies, Inc., Santa Clara, CA, USA) and PL-Grid Infrastructure. The differences were analysed using the Oneway ANOVA test with Benjamini-Hochberg Multiple Testing Correction and TukeyHSD Post Hoc test. Genes were considered as potentially differentiating when $FC \geq 1.1$ (fold change) and the significance level was set at $p < 0.05$.

Real-time QRT-PCR

The levels of the *DEFB4A* and β -actin transcripts were evaluated with the use of the real-time QRT-PCR TaqMan technique. The quantitative analysis was carried out using a Sequence Detector ABI PRISM[™] 7000 (Applied Biosystems, Foster, CA, USA). Amplification was performed with the use of commercially available oligonucleotide primers specific for *DEFB4A* and β -actin genes (*DEFB4A*: TaqMan Gene Expression Assay defensin, beta 4; β -actin: TaqMan B-actin Detection Reagents Kit, Applied Biosystems, Inc.,

Foster, CA, USA) and QuantiTect Probe RT-PCR Kit (Qiagen GmbH, Hilden, Germany). For the assay, positive (β -actin mRNA) and negative (no template) controls were used. The thermal profile for one-step RT-PCR was as follows: 50°C for 30 min for reverse transcription, 95°C for 15 min, 45 cycles at 94°C for 15 s and at 60°C for 60 s. The standard curve was created for β -actin cDNA (TaqMan DNA Template Reagents Kit, Applied Biosystems, Inc., Foster, CA, USA). A standard curve was then generated by plotting the Ct values against the log of the known amount of the β -actin cDNA copy number. The mRNA copy numbers of the gene examined were recalculated per 1 μ g of the total RNA. The RT-PCR products and the molecular weight marker pBR 322/Hae III (Fermentas International Inc., Ontario, Canada) were separated on 8% polyacrylamide gel and visualised with silver salts. The length of the amplified fragments was assessed by analysis with GelScan v.1.45 software (Kucharczyk TE, Warsaw, Poland). The statistical analysis of the real-time QRT-PCR results was performed with the use of Statistica version 9.0 software (StatSoft Inc., Oklahoma, USA). The one-way ANOVA followed by Tukey posthoc analysis of the logarithmic parameters were used to assess differences in the expression of the studied genes between KA, SCC and BCC. The differences between the tumour and the margin of the normal tissue were analysed using the t-test. All of results were expressed as means \pm SD. The significance level was set at $p < 0.05$.

RESULTS

Microarray analysis

In the present study, changes in transcriptome of defensin family genes and genes coding proteins involved in their activation in non-melanoma skin pathologies were evaluated. Among 251 ID mRNA of defensin-related genes found in Affymetrix database (<http://www.affymetrix.com>) 11 transcripts were differentiating in non-melanoma skin pathologies (Oneway ANOVA test with Benjamini-Hochberg Multiple Testing Correction) (tab. 1A). Comparing to controls (C) 5 transcripts were differentiating for keratoacanthoma (KA), 4 for squamous cell carcinoma (SCC) and 2 for basal cell carcinoma (BCC) (TukeyHSD Post Hoc test) (tab. 1B).

Among 11 transcripts 6 were differentiating in comparison to controls (fig. 1). Some of them were characteristic only for particular group of transcriptomes, some were common for few groups. *DUSP7* was characteristic only for KA and *TRAF3* was characteristic only for SCC. *S100A8* and *S100A9* were common for KA and SCC. *MAPKAPK2* was common for KA and BCC. *DEFB4A* was common for all transcriptomes, comparing to controls (KA, SCC, BCC).

Keratoacanthoma transcriptomes comparing to BCC showed 3 upregulated genes (*S100A9*, *DUSP6*, *DUSP7*) and one gene down-regulated (*PELI2*). Comparing to SCC also *DUSP6* and *DUSP7* were up-regulated, while *TRAF3* was down-regulated in KA.

Table 1. The results of statistical analysis of 251 ID mRNA defensin-related genes in non-melanoma skin pathologies. A – The results of Oneway ANOVA test with Benjamini-Hochberg Multiple Testing Correction showing 11 differentiating entities at $p < 0.05$. B – TukeyHSD Post Hoc test results. Entities found to be differentially expressed between particular groups of samples are represented by grey colour.

A	P-value	P all	$p < 0.05$	$p < 0.02$	$p < 0.01$	$p < 0.005$	$p < 0.001$
	Number of ID mRNA	251	11	2	2	2	1
	Transcriptomes	KA	SCC	BCC		C	
B	KA	11	3	5		5	
	SCC	8	11	3		4	
	BCC	6	8	11		2	
	C	6	7	9		11	

KA – keratoacanthoma; SCC – squamous cell carcinoma; BCC – basal cell carcinoma; C – controls (healthy skin margins)




Fig. 1. Venn diagram showing number of transcripts differentiating in comparison to controls common for groups of transcriptomes: KA – keratoacanthoma, SCC – squamous cell carcinoma, BCC – basal cell carcinoma, C – controls (healthy skin margins).

In comparison of SCC to BCC *TRAF3* and *MAPK3* were upregulated, *LGR4* was down-regulated in SCC (fig. 2).

The most differentiating gene was *DEFB4A* which expression was upregulated in all skin non-melanoma pathologies comparing to controls. The highest fold change was for SCC (FC = 13.35), for KA FC = 9.86 and for BCC FC = 7.86.

Real-time QRT-PCR

In the next step the transcript level of the *DEFB4A* gene was validated using the QRT-PCR assay. The

DEFB4A mRNA level was higher in non-melanoma skin tumours than in the margins of the healthy tissue (tab. 2). Analysis of the *DEFB4A* transcript level in the tumours revealed significant difference between BCC, KA and SCC. The *DEFB4A* mRNA level in BCC was lower than in the KA and SCC groups ($p = 0.0018$, $p = 0.0014$, respectively; Tukey’s test). No statistically significant difference was found between KA and SCC ($p = 0.9902$) in the mRNA level of the *DEFB4A* gene. The *DEFB4A* transcript level in the margins of the healthy tissue was comparable ($p = 0.3101$).

Table 2. *DEFB4A* mRNA level in KA, SCC, BCC, C.

	KA	SCC	BCC	p^a
Tumour	5.32 ± 0.74	5.21 ± 0.55	4.39 ± 0.59	0.0002
Margin	4.03 ± 1.22	4.42 ± 0.96	3.83 ± 1.11	NS
p^b	0.0051	0.0123	0.0315	

KA – keratoacanthoma; SCC – squamous cell carcinoma; BCC – basal cell carcinoma; C – controls (healthy skin margins); mean ± standard deviation; NS – not significant

^aANOVA

^bt test

Additionally, the expression of the β -actin gene was assessed as an endogenous control. The transcript level of this gene was similar in tumours and healthy tissues. Statistical analysis revealed a marked difference in the β -actin mRNA level in the tumours. However, the number of mRNA copies in the BCC group was lower than that in the KA group ($p = 0.0012$; Tukey’s test). In common with that found for the *DEFB4A* gene, the β -actin mRNA level in the margins of the healthy tissues was comparable ($p = 0.7467$).




Fig. 2. Heat-map for differentiating ID mRNA of defensin-related genes in transcriptomes of KA – keratoacanthoma, SCC – squamous cell carcinoma, BCC – basal cell carcinoma, C – controls (healthy skin margins).

DISCUSSION

Defensins through multidirectional activity may influence many biological processes, including regulation of inflammatory response and wound healing (2). Many risk factors of NMSC (non-melanoma skin cancers) and KA can influence immunological reaction, thus potential involvement of defensins in mechanism underlying these pathologies cannot be excluded. Moreover, self-regression of KA is, *inter alia*, caused by changes in immunological reaction together with defensins' activity (21). There is much controversy whether KA should be described as a mild or intermediate form of SCC or whether it should be considered as a totally separate benign malignancy (12, 13). KA needs to be differentiated from both SCC and BCC. Some studies have been carried out to differentiate KA and SCC, other have compared molecular changes in SCC and BCC (16, 22-25). Comparing all three pathologies together could show changes helpful in differentiating KA from BCC and SCC, as well as SCC from BCC. Moreover, such approach could reveal molecular markers which could have impact on self-regression of KA. Therefore the aim of this study was to evaluate changes in mRNA profile of defensin family genes and genes coding proteins involved in their activation in three non-melanoma pathologies: KA, SCC and BCC in one study.

mRNA profiles of KA, BCC and SCC transcriptomes were appointed with the use of oligonucleotide microarrays (HGU133A, Affymetrix). Statistical analysis of transcriptomes assumed 251 ID mRNA of genes coding defensins and proteins involved in their activation, based on Affymetrix database results. Eleven ID mRNA were differentiating comparing to control samples. The only characteristic gene for KA was *DUSP7*, which expression was the highest in KA and it differentiated this lesion from controls, BCC and SCC. Additionally *DUSP6* was also upregulated in KA, but only in comparison to SCC and BCC. *DUSP7* and *DUSP6* encode phosphatases which inactivate the MAP kinases ERK1/2 (26, 27). ERK1/2 are responsible for proliferation of skin SCC and inhibition of this pathway is crucial in anti-tumour therapy (28). Our research showed up-regulated *MAPK3* (*ERK1*) in SCC, comparing to BCC. Together with down-regulation of DUSP inactivators this result shows crucial role of ERK pathway in SCC. Moreover, the characteristic gene for SCC was *TRAF3*, which was upregulated in SCC comparing to controls, BCC and KA. *TRAF3* is positive regulator of PI3K/AKT and JAK/STAT signalization and controls the growth of B and T cells (29). Both in KA and SCC, *S100A8* and *S100A9* were upregulated comparing to controls. *S100A9* was also upregulated in KA in comparison to BCC. *S100A8* and *S100A9* are calcium-binding proteins, highly expressed at sites of acute and chronic inflammation including psoriatic epidermis (30). These two proteins forms calprotectin, a heterodimeric complex which activate NF- κ B signalization. Their high level was reported in inflammation, carcinogenesis and also during wound healing (30). Upregulated genes in BCC

were *PELI2* (comparing to KA) and *LGR4* (comparing to SCC). *PELI2* takes a part in TAK1 dependent activation of NF- κ B, as well as in ERK phosphorylation (31). *LGR4*, G-protein-coupled receptor is crucial in the regulation of Wnt signalling (32). Common upregulated marker for KA and BCC was *MAPKAPK2* (*MK2*). This gene is coding serine/threonine kinase phosphorylated by p38 mitogen-activated protein kinase and plays a crucial role in inflammatory response (33). The participation of *MK2* in immunological reaction along with protection of cells with DNA damage from apoptosis means that this kinase is crucial in skin tumours' development (33).

In all skin non-melanoma pathologies upregulated gene was *DEFB4A* (the official symbol of *defensin beta 2* – *HBD2*, according to HUGO Gene Nomenclature Committee). *DEFB4A* belongs to the defensin family of small cationic peptides. It is produced by keratinocytes during inflammatory reactions, and it is present in lamellar bodies of the stimulated keratinocytes in the granular epidermal layer, in the extracellular matrix and in the stratum corneum (34, 35). *DEFB4A* is a protein closely associated with the development and maintenance of inflammation in the skin. It activates many mechanisms of adaptive and innate immune responses, which eventually lead to development of a local inflammatory response. Earlier research evaluated defensin beta 2 in relation to numerous pathologies: psoriasis and atopic dermatitis, irritable bowel syndrome, lung cancer, bacterial infections, BCC and SCC (3, 6, 8, 36-40). In our study oligonucleotide microarray analysis showed that the greater difference in *DEFB4A* mRNA level in comparison to controls was in SCC (FC = 13.35), in KA this difference was lower (FC = 9.86) and the lowest was in BCC (FC = 7.86). Significant fact is that all these non-melanoma skin pathologies showed up-regulation of this gene. Until now, there has been no study concerning *DEFB4A* mRNA expression in KA, SCC and BCC simultaneously.

In the present study, the level of defensin beta 2 mRNA in KA, SCC and BCC was validated by the use of real-time QRT-PCR. Due to a marked difference between the analysed tumours, the expression of β -actin mRNA could not be used for normalisation of the results obtained. Thus, the number of mRNA copies was recalculated per microgram of total RNA. All of the tumours analysed showed higher expression of *DEFB4A* mRNA compared with the margins of the healthy tissues. Our results are in agreement with other published data. Gambichler et al. demonstrated up-regulation of *DEFB4A* mRNA in BCC compared with healthy controls (8). In oral SCC, Yoshimoto et al. observed the expression of *HBD-2* both in inflamed lesions with bacterial infection and non-inflamed carcinomas using the *in situ* hybridization technique (41). Moreover, they demonstrated the expression of *HBD-2* in normal oral epithelia only in areas adjacent to the SCCs. Shi et al. reported overexpression of *HBD-2* in rat

oesophageal squamous cell carcinoma (SCC) and in oesophageal SCC tissues in patients (6). We compared the mRNA level of the *DEFB4A* gene between KA, SCC and BCC. The expression was significantly higher both in KA and SCC compared with BCC. Our results showed that the expression of *DEFB4A* mRNA is similar in KA and SCC. However, such similarity does not indicate the same outcome in these two tumours. Defensin beta 2 is one of the most important factors involved in the immunological reaction and keratinisation. In KA, induction of the immune response, which inhibits uncontrolled growth and limits the proliferation potential of KA cells, may lead to its regression (21). Furthermore, the regression of KA may be related to the cessation of the differentiation of the cells, which become keratinised and are not able to proliferate any more, and, therefore, die. The cessation of the tumour cells' differentiation is then manifested by keratinisation. Yoshimoto et al. suggested that HBD-2 may lead to the death of

normal keratinocytes adjacent to the SCCs, which might, in turn, indirectly assist in the multiplication of tumour cells (41). The molecular mechanism underlying KA transformation into SCC is still unclear. Probably, transformed cells (SCC) present in the KA tumour proliferate during the keratinisation of KA. Along with changes at mRNA level of genes coding proteins involved in intracellular signalization of KA common for BCC and SCC, changes in *DEFB4A* expression suggest complex interactions at protein level of unknown results. Therefore, planning therapeutic approaches to KA based on stimulation of the *DEFB4A* gene expression should be considered carefully.

The defensin beta 2 mRNA level may constitute a useful tool for the differentiation of BCC from KA and from SCC. KA and SCC cannot be differentiated on the basis of the *DEFB4A* mRNA level. To definitely confirm the usefulness of the expression of *defensin beta 2* in differentiation of KA from SCC and BCC, more detailed studies of larger populations are needed.

BIBLIOGRAPHY

- Niedzwiedzka-Rystwej P, Deptula W: Defensins: an important innate element of the immune system in mammals. *Postepy Hig Med Dosw* 2008; 62: 524-529.
- McDermott AM, Redfern RL, Zhang B et al.: Defensin expression by the cornea: multiple signalling pathways mediate IL-1beta stimulation of hBD-2 expression by human corneal epithelial cells. *Invest Ophthalmol Vis Sci* 2003; 44: 1859-1865.
- Morizane S, Gallo RL: Antimicrobial peptides in the pathogenesis of psoriasis. *J Dermatol* 2012; 39(3): 225-230.
- Tanghetti EA: The role of inflammation in the pathology of acne. *J Clin Aesthet Dermatol* 2013; 6(9): 27-35.
- Harder J, Dressel S, Wittersheim M et al.: Enhanced expression and secretion of antimicrobial peptides in atopic dermatitis and after superficial skin injury. *J Invest Dermatol* 2010; 130(5): 1355-1364.
- Shi N, Jin F, Zhang X et al.: Overexpression of human β -defensin 2 promotes growth and invasion during esophageal carcinogenesis. *Oncotarget* 2014; 5(22): 11333-11344.
- Haider AS, Peters SB, Kaporis H et al.: Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. *J Invest Dermatol* 2006; 126(4): 869-881.
- Gambichler T, Skrygan M, Huyn J et al.: Pattern of mRNA expression of β -defensins in basal cell carcinoma. *BMC Cancer* 2006; 6: 163.
- Zargaran M, Baghaei F: A clinical, histopathological and immunohistochemical approach to the bewildering diagnosis of Keratoacanthoma. *J Dent Shiraz Univ Med Sci* 2014; 15(3): 91-97.
- Tan KB, Tan SH, Aw DC et al.: Simulators of Squamous Cell Carcinoma of the Skin: Diagnostic Challenges on Small Biopsies and Clinicopathological Correlation. *J Skin Cancer* 2013; 2013: 752864.
- Ramos LM, Cardoso SV, Loyola AM et al.: Keratoacanthoma of the interior lip: review and report of case with spontaneous regression. *J Appl Oral Sci* 2009; 17: 262-265.
- Lanssens S, Ongenaes K: Dermatologic lesions and risk for cancer. *Acta Clin Belg* 2011; 66: 177-185.
- Archontaki M, Korkolis DP, Arnoglannaki N et al.: Giant Basal cell carcinoma: clinicopathological analysis of 51 cases and review of the literature. *Anticancer Res* 2009; 29: 2655-2663.
- Van der Geer S, Ostertag JU, Krekels GA: Treatment of basal cell carcinomas in patients with nevoid basal cell carcinoma syndrome. *J Eur Acad Dermatol Venereol* 2009; 23: 308-313.
- Buljan M, Bulat V, Situm M et al.: Variations in clinical presentation of basal cell carcinoma. *Acta Clin Croat* 2008; 47: 25-30.
- Sari Aslani F, Akbarzadeh-Jahromi M, Jowkar F: Value of CD10 Expression in Differentiating Cutaneous Basal from Squamous Cell Carcinomas and Basal Cell Carcinoma from Trichoepithelioma. *Iran J Med Sci* 2013; 38(2): 100-106.
- Koyuncuer A: Histopathological evaluation of non-melanoma skin cancer. *World J Surg Oncol* 2014; 12: 159.
- Andersson K, Michael KM, Luostarinen T et al.: Prospective study of human papillomavirus seropositivity and risk of nonmelanoma skin cancer. *Am J Epidemiol* 2012; 175(7): 685-695.
- Situm M, Buljan M, Bulat V et al.: The role of radiation in the development of basal cell carcinoma. *Coll Antropol* 2008; 32: 167-170.
- Bzhalava D, Johansson H, Ekstrom J et al.: Unbiased Approach for Virus Detection in Skin Lesions. *PLoS ONE* 2013; 8(6): e65953. doi:10.1371/journal.pone.0065953.
- Elston DM: Mechanisms of Regression. *Clin Med Res* 2004; 2: 85-88.
- Pyne JH, Windrum G, Sapkota D, Wong JC: Keratoacanthoma versus invasive squamous cell carcinoma: a comparison of dermatoscopic vascular features in 510 cases. *Dermatol Pract Concept* 2014; 4(3): 6.
- Lin MJ, Pan Y, Jalilian C, Kelly JW: Dermoscopic characteristics of nodular squamous cell carcinoma and keratoacanthoma. *Dermatol Pract Concept* 2014; 4(2): 2.
- Kambayashi Y, Fujimura T, Aiba S: Comparison of Immunosuppressive and Immunomodulatory Cells in Keratoacanthoma and Cutaneous Squamous Cell Carcinoma. *Acta Derm Venereol* 2013; 93: 663-668.
- Muehleisen B, Jiang SB, Gladsjo JA et al.: Distinct Innate Immune Gene Expression Profiles in Non-Melanoma Skin Cancer of Immunocompetent and Immunosuppressed Patients. *PLoS ONE* 2012; 7(7): e40754. doi:10.1371/journal.pone.0040754.
- Carlos AR, Escandell JM, Kotsantis P et al.: ARF triggers senescence in Brca2-deficient cells by altering the spectrum of p53 transcriptional targets. *Nat Commun* 2013; 4: 2697.
- Toriseva M, Ala-aho R, Peltonen S et al.: Keratinocyte Growth Factor Induces Gene Expression Signature Associated with Suppression of Malignant Phenotype of Cutaneous Squamous Carcinoma Cells. *PLoS ONE* 2012; 7(3): e33041. doi:10.1371/journal.pone.0033041.
- Zhang X, Makino T, Muchemwa FC et al.: Activation of the extracellular signal-regulated kinases signaling pathway in squamous cell carcinoma of the skin. *Biosci Trends* 2007; 1(3): 156-160.
- Muro I, Fang G, Gardella KA et al.: The TRAF3 adaptor protein drives proliferation of anaplastic large cell lymphoma cells by regulating multiple signaling pathways. *Cell Cycle* 2014; 13(12): 1918-1927.
- Schonthaler HB, Guinea-Viniegua J, Wculek SK et al.: S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3. *Immunity* 2013; 39(6): 1171-1181.
- Kim TW, Yu M, Zhou H et al.: Pellino 2 is critical for Toll-like receptor/interleukin-1 receptor (TLR/IL-1R)-mediated post-transcriptional control. *J Biol Chem* 2012; 287(30): 25686-25695.
- Du B, Luo W, Li R et al.: Lgr4/Gpr48 negatively regulates TLR2/4-associated pattern recognition and innate immunity by targeting CD14 expression. *J Biol Chem* 2013; 288(21): 15131-15141.
- Johansen C, Vestergaard C, Kragballe K et al.: MK2 regulates the early stages of skin tumor promotion. *Carcinogenesis* 2009; 30(12): 2100-2108.

34. Oren A, Ganz T, Liu L, Meerloo T: In human epidermis, beta-defensin 2 is packaged in lamellar bodies. *Exp Mol Pathol* 2003; 74: 180-182.
35. Dinulos JG, Mentele L, Fredericks LP et al.: Keratinocyte expression of human beta defensin 2 following bacterial infection: role in cutaneous host defense. *Clin Diagn Lab Immunol* 2003; 10: 161-166.
36. Jansen PA, Rodijk-Olthuis D, Hollox EJ et al.: Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. *PLoS One* 2009; 4: e4725.
37. Langhorst J, Junge A, Rueffer A et al.: Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. *Am J Gastroenterol* 2009; 104: 404-410.
38. Shestakova T, Zhuravel E, Bolgova L et al.: Expression of human beta-defensins-1, 2 and 4 mRNA in human lung tumor tissue: a pilot study. *Exp Oncol* 2008; 30: 153-156.
39. Shestakova T, Zhuravel E, Bolgova L et al.: Immunohistochemical analysis of beta-defensin-2 expression in human lung tumors. *Exp Oncol* 2010; 32: 273-276.
40. Han S, Bishop BM, van Hoek ML: Antimicrobial activity of human beta-defensins and induction by *Francisella*. *Biochem Biophys Res Commun* 2008; 371: 670-674.
41. Yoshimoto T, Yamaai T, Mizukawa N et al.: Different expression patterns of beta-defensins in human squamous cell carcinomas. *Anticancer Res* 2003; 23: 4629-4633.

received/otrzymano: 02.02.2015
accepted/zaakceptowano: 26.02.2015